Safe, effective procedures
Shorter procedures
Simpler procedures

Jeremy N. Ruskin, MD
Founder and Director Emeritus; 

Cardiac Arrhythmia Service, Massachusetts General Hospital;

Professor of Medicine, Harvard Medical School

Advantages

Features

“Ablacor’s novel approach of a circular ablator, with its controlled electrode-tissue contact, designed to generate continuous and transmural ablation lesions reliably, holds great promise and would be a major advance.” 

AblaCor™ Medical Corporation’s mission is to develop innovative products to significantly advance Atrial Fibrillation (AFib) treatment. The Company’s goal is to provide patients with long-term freedom from AFib without multiple ablation procedures.  

AblaCor’s first product, the Circum
Blator™ AF Catheter Ablation System, is uniquely designed to deliver pulmonary vein isolation (PVI) in a “single-shot" circumferential ablation compared to currently marketed “point-by-point” and “balloon” technologies.

AblaCor is advancing

Cardiac Ablation 


Click here for pdf of our Company Fact Sheet


Advancing

Cardiac Ablation


AblaCor's Scientific Advisors

Copyright © AblaCor Medical Corporation. All Rights Reserved.

The CircumBlator™ AF Catheter Ablation System is not approved for human use.

Benefits

Continuous tissue contact for precise lesion formation the first time

Improved patient outcomes
Fewer repeat procedures
Reduced healthcare costs 

Lawrence S. Rosenthal MD, PhD, FACC, FHRS 
Director, Electrophysiology Service;  

Professor of Medicine, UMass Memorial Medical Center 

Stabilizing anchor
Adaptable electrodes
Controlled energy delivery